MUC16CD CAR T cells

MUC16CD CAR T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy targeting Muc16CD, the retained C-terminal ectodomain of Mucin 16 (CA-125) that remains on the tumor cell surface following cleavage. This therapy is primarily being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer, where MUC16 is highly expressed. A specialized armored version of this therapy, designated as CAR/VIPRa, incorporates the secretion of vasoactive intestinal peptide receptor (VIPR) antagonist peptides. This modification is designed to counteract the immunosuppressive effects of the VIP checkpoint pathway, which is prevalent in the PDAC tumor microenvironment. Preclinical data suggests that these armored CAR T cells exhibit improved metabolic profiles, enhanced persistence, and superior anti-tumor activity compared to standard CAR T cells. The development is led by researchers at Emory University, with associations to MIGRA-Therapeutics.

Other names

Muc16CD-directed CAR T cellsMuc-16CD-directed CAR T cellsMuc 16CD-directed CAR T cellsMuc16CD-directed armored CAR T cellsMuc-16CD-directed armored CAR T cellsMuc 16CD-directed armored CAR T cells